Cyprotex Share Discussion Threads

[p1nkfish] 07/9/2015 23:08

Break out looming.
Would be about time.

Still have visions of this breaching £1.20 and would be pleased to see Baxter get his shares/bonus. May be another 2-3 years before then but with the right news much sooner.

[buywell3] 07/9/2015 17:34

I have a feeling that the FTSE 100 chart and CRX chart in the header, will soon be Xing each other again

But going in different directions

And it will be the FTSE going down as more bad news from China comes out over the rest of this week

Safe Haven Sectors and profit making small caps within those sectors looks best to me as the FTSE 100 stocks now behave like poor quality AIM stocks in the stormy winds that blow from the Far East ................... ( China is in the Far East )

All we need now is for a nice Trading Update with news of a juicy contract win.

[buywell2] 06/9/2015 07:52

.............. NEW PRE - CLINICAL TOXICOLOGY DEVELOPMENT ...............

India puts an end to repeat animal test for new drugs

Aug 25, 2015




I have posted many times about the use of animals in toxicology testing of new drug compounds.

They are no better than a 50/50 coin flip and quite often give the opposite results than those in humans. Which is why so many drugs get withdrawn after being approved by the FDA ,EMA and other regulatory authorities.

$ BILLIONS of dollars are wasted by BIG Pharma when a drug gets withdrawn after approval, not just the $ 2 BILLION (Forbes says $5 Billion) typical cost for the development ( up to 15 years ) but also the $ BILLIONS in Class Action Lawsuits that follow.

It is around HALF A CENTURY ago that the FDA stipulated the use of 1 rodent species and 1 non-rodent species in Toxicology tests on new drug compounds.

Not surprising an industry providing animals for these mandated FDA Toxicology tests has evolved. This industry is worth $ Billions just by itself and those invested in it don't want change.






It is interesting therefore to read that India has taken what I believe is a first important step in what will ultimately lead to a ban on the use of animals for pre-clinical Acute Toxicology tests by probably the EU next and then the FDA in the USA.


Acute toxicology tests involve the death of the animal , this will be the FIRST ban , the ban will be based upon better data using human 'cell based assays' for acute toxicology tests , where living 3D structures of human cells from specific organs give results that

......... '' ARE 50% BETTER THAN THOSE OBTAINED USING ANIMALS '' ............




India puts an end to repeat animal test for new drugs

Aug 25, 2015 -

India has decided doing away with “repeat” animal testing for permission for a new drug. The Drug Technical Advisory Board (DTAB), government’s chief advisory body, in its recent meeting decided to explore using other alternative methods other than animal studies. According to the advisory board, for drugs approved in other countries where complete toxicological data is generated, further toxicology study may not be required.

Earlier, minister for women and child development Maneka Gandhi had written to the health minister regarding pre-clinical and toxicity studies on animals under the Drugs and Cosmetics Rules, 1945.

It was stated that India being signatory of Organisation for Economic Cooperation and Development Council Act, according to which mutual acceptance of data was under obligation and it states to respect the data generated by other country regarding pre-clinical/toxicity studies, there was no need for India’s Central Drug Standard Control Organisation (CDSCO) to undertake further studies.

However, under the current regulations additional tests on animals are then too ordered.

The matter was taken up by Investigational New Drug Committee earlier this month.

It also suggested that toxicity may not be required if complete data, as per prescribed requirements, is submitted during application for new drug approval.

The committee further suggested to explore in line with international practices to encourage the use of alternative methods other than animal studies.

Following the IND committee recommendations, the DTAB after deliberations agreed to it and further recommended that if authentic data on animal toxicology has been submitted with the technical data then “repeat” animals testing for permission for the new drug or clinical trial is not necessary.

The novel step, according to officials will further help in stopping unnecessary cruelty on animals. Recently, India also imposed ban on the import of cosmetics that have been tested on animals.

[buywell3] 01/9/2015 07:35

The actual chemical structure of a new drug compound ie all the molecules present and the way they bond together, are made public when clinical trial results are published.

Thus we get 2 outcomes good results indicating efficacy and no adverse toxic effects

And drugs that produce no noticable efficacy or produce toxic effects

A bit simplistic some may think, as there are a few grey areas, but ....


Re the Pharma industry it is either money spent wisely or money wasted

Thus it seemed a good idea to be able to create a predictive computer tool that gathered the data from the chemical molecules from drug compounds that had failed clinical studies ie a BAD outcome for BIG Pharma & another set of data from the chemical molecules from those new drug compounds that got approval and passed clinical trials ie a GOOD Pharma outcome.

Such a tool can quite easily run through another new untested drug compound given it's chemical molecule details and compare V all the existing data entered data from actual clinical trials going back MANY years ie a BIG databank.

Thus I liked this , and better still that it was a great fit for the new BioSciences Division of the company.

The FDA likes such predictive computer based technology







Advances in PBPK Modelling – Predicting Pharmacokinetics Directly from Chemical Structure

chemPK pharmacokinetics prediction

Posted 15th July 2015 by Cyprotex

PBPK (physiologically based pharmacokinetic) modelling is a mathematical technique used to predict the in vivo pharmacokinetics (PK) of a xenobiotic (such as a drug or other compound), using information relating to its ADME (absorption, distribution, metabolism and excretion) properties. This approach typically involves developing a multi-compartment model in which the compartments represent the major organs and tissues in the body, whilst the connections between compartments represent their interconnecting blood flows. Within the PBPK model, complex ADME processes are modelled by incorporating anatomical, physiological, biochemical and chemical information, including physiochemical data and in vitro ADME data.

As these models typically require in vitro data, their implementation within the drug discovery process normally only occurs during the lead optimisation phase or later. Methods used to predict PK directly from structure do exist, but often rely on QSAR-based methods which tend not to be as robust as PBPK models optimised directly on human clinical data.

chemPKTM is a new product on the market that can predict the key human PK properties AUC, Cmax and Tmax directly from chemical structure using a PBPK model optimised on human clinical PK data. This has the potential to revolutionise the drug discovery process by providing insight into the key pharmacokinetic parameters, before the compound has even been synthesised. Medicinal chemists and computational chemists now have a virtual screening tool that can assist in directing their chemistry and prioritising their future screening activities by taking into account the predicted exposure of their compounds in humans.

Daniel Mucs PhD, a mathematical modeller at Cyprotex, has played a major role in developing the chemPKTM workflow solution. An overview of the technology, as implemented as a set of nodes within the KNIME Analytics Platform, a workflow management system popular for cheminformatics, is presented by Daniel in the following video.

Watch the chemPKTM video.

[buywell3] 28/8/2015 13:12

It looks like there are some additional jobs on the Cyprotex website

And one of the vacancies is for several technicians on a 12 month contract, this has only been added in the last couple of weeks.

My read of this , is that Cyprotex have recently landed a decent sized contract but as per normal the Client has stiplulated that Cyprotex can't disclose details. Note High ThroughputScreening (HTS) robotics are mentioned which means high volume testing.



Current Positions

Laboratory Assistant - Macclesfield, UK


Laboratory Assistant(s) Physical Chemistry Team – 12 month contract - Macclesfield, UK

Position Purpose:

To work closely with other laboratory staff to ensure that experimental aspects of in vitro ADMET studies are performed to a high standard and within scheduled time frames. This vacancy will be based at our site in Macclesfield and is a temporary 12 month contract.

Principal Accountabilities

Support high and low throughput ADMET screening processes for commercial as well as research and development activities
Perform work to a high quality, within specified timelines, and within safety regulations
Assist in running and maintaining robotic systems to support high throughput ADMET processes
Assist in data analysis and interpretation
Prepare compounds, stock solutions and buffers
Routine calibration of laboratory equipment

Experience

Minimum of BSc in a life science subject preferably with experience of working within a laboratory environment (such as a placement year or extended research project)
Previous experience of laboratory processes would be advantageous

Skills & Competencies

Highly self-motivated and personable
Able to communicate effectively within a team environment
Able to organise daily tasks, to frequently work under pressure and to meet tight deadlines
Possess excellent attention to detail, performing work to an exceptionally high standard, and within company and statutory safety regulations
Able to use initiative to solve problems and troubleshoot with the assistance of other members of the team
Should be computer literate with previous experience using Microsoft Office

Development Opportunities

To gain knowledge and understanding of high and low throughput screening processes and ADMET in early drug discovery and development
To work with a number of different robotic and laboratory management systems
To work in a highly motivated commercial environment
To gain a sound understanding of the theory behind a variety of ADMET screening assays

[buywell2] 27/8/2015 07:39

The Cyprotex/CeeTox acquisition also provided Cyprotex with a range of Endocrine Disruptor testing and IP , which the EPA in the USA awarded a 5yr contract on worth up to $130M and is still running now


Potentially this market alone could in my opinion be a game changer for Cyprotex when the authorities are forced to bite the bullet and implement such tests on thousands of untested chemicals that are affecting fetuses , babies and adult human beings , mammals, fish , crustaceans and invertebrates, ie every living creature on the planet.

Such chemicals are cancer causing and also affect the species reproductive capabilities in a variety of bad ways which Governments don't want their plebs to know about because they are being paid by big buisiness to delay and fudge issues.

Some countries like France are leading the fight , which is funny because I ain't keen on Frogs unless they are served crispy with lots of garlic sauce.





The latest on Endocrine Disruptors re the EPA in the USA ( Cyprotex contract)






An Update on the US EPA Endocrine Disruption Screening Program


US EPA EDSP - Endoncrine Disruptor Screening Program

Posted 5th August 2015 by Cyprotex



Recently, the United States Environmental Protection Agency (US EPA) released results of Tier 1 EDSP (Endocrine Disruptor Screening Program) testing for 52 pesticides. Through a Weight of Evidence approach, results of this first round of screening will be used to determine which chemicals should be placed through more rigorous (and animal-based) testing.

Currently, Tier 1 screening is comprised of 11 assays; five of which are in vitro and six are in vivo. The EPA is evaluating the applicability of high-throughput (HT) systems for Tier 1 EDSP assays with favourable results. Combination of data from HT screening and computational modelling using ToxCast™ data have so far led to the proposed acceptance of alternative, animal-free in vitro assays for Estrogen Receptor (ER) Binding, Estrogen Receptor Transactivation (ERTA) and Uterotrophic screening. In vitro alternatives for male and female rat pubertal, Androgen Receptor (AR) Binding, Aromatase, Steroidogenesis and the other Tier 1 assays remain under development. By the EPA’s official estimation, HT endocrine disruption testing could save as much as 90% of the cost and 75% of the time required per chemical, while entirely forgoing the need for animal testing for certain hormonal systems that may interact with chemicals.

An important component in the ongoing development of in vitro endocrine disruption screening is the Toxicology in the 21st Century (Tox21) consortium, which is made up of members from the EPA, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). As of 18 June, 2015, Tox21 had provided estrogen screening results from HT systems for 1800 chemicals, with the results of an additional 1200 expected by 2016. It is important to note, however, that these data reflect estrogen receptor pathways specifically. Development and evaluation of in vitro assays for the androgen and thyroid pathways is incomplete.

Tier 2 EDSP testing is only required for chemicals where more test data are required to fully understand their impact on the endocrine system. This testing examines life cycle and generational impacts of chemicals thought to have endocrine disruption potential. These studies look at how a compound can effect an organism over time and whether or not any observed effects manifest in offspring. Because of the longitudinal nature of Tier 2 assays, there are no viable options for in vitro alternative methods. These tests, however, provide critical insight into the long-term effects chemicals can have on the environment.

Learn more about the in vitro EDSP Tier 1 assays:
• Estrogen Receptor (ER) Binding
• Estrogen Receptor Transactivation (ERTA)
• Androgen Receptor (AR) Binding
• Aromatase
• Steroidogenesis

[buywell3] 26/8/2015 18:12

This latest Cyprotex US development looks promising ... could mean a boost for Cyprotex USA dollar earnings next year perhaps





Cyprotex US selected as a member of the Consortium for in vitro Eye Irritation testing strategy (CON4EI)

CON4EI - In vitro OECD eye irritation

Posted 25th August 2015 by Cyprotex

In 2014, the European Chemical Industry Council (Cefic) launched a research initiative to investigate in vitro testing strategies for eye irritation. Based on this initiative, a consortium, led by the Flemish Institute for Technological Research (VITO), has been formed and is named the Consortium for in vitro Eye Irritation testing strategy, or CON4EI.

In total, eight different groups including Adriaens Consulting bvba, L’Oréal Research & Innovation, Institute of Industrial Organic Chemistry, Envigo, MatTek, In Vitro Life Science Laboratories, Ghent University – Laboratory of Pharmaceutical Sciences and Cyprotex are part of the Consortium, and these partners are conducting eight test methods, with results to-date being presented at Eurotox 2015 in Porto, Portugal and the EUSAAT congress in Linz, Austria. Both conferences take place next month.

80 chemicals have been selected based on existing in vivo data and will be testing in the following test methods:

Distinguish between UN GHS Category 1 and No Category

Bovine Corneal Opacity and Permeability (BCOP) – OECD Test Guideline 437
Isolated Chicken Eye (ICE) – OECD Test Guideline 438
Short Time Exposure (STE) – OECD Test Guideline 491
Distinguish between UN GHS Category 1/Category 2 and Not Classified
EpiOcular™ Eye Irritation Test (EIT) – OECD Test Guideline 492
SkinEthic™ Human Corneal Epithelial (HCE)

Distinguish between UN GHS Category 1 and Category 2

Histopathology in association with BCOP and ICE
EpiOcular™ ET-50 (time-to-toxicity test)
Slug Mucosal Irritation (SMI)
BCOP-laser light-based opacitometer (BCOP-LLBO)


Cyprotex US has been selected to perform the Short Time Exposure (STE) for Serious Eye Damage on these 80 test articles on the behalf of CON4EI.

Following test completion and data delivery, the reliability of the in vitro methods will be evaluated, areas of applicability will be assigned and the strengths and limitations of each method will be assessed. Ultimately, a tiered approach will be created based on applicable test methods that can distinguish UN GHS No Category versus Category 1 and Category 2 versus Category 1.

[p1nkfish] 22/8/2015 22:26

There are still outside services used that can be brought inside to help the already high gross margin.

Often easier to cut costs than drive revenue higher but in this case they have the growth in revenue available anyway. SP/Sales alone is attractive as they can cut costs if needed. Double whammy potential.

I added last week and averaged up.

Good luck everyone over the next 3-5.

[buywell2] 21/8/2015 08:46

Nice charts b3 , but words also 'don't come easy' for many do they ? hence


...... In a worrying time re China , reasons to be cheerful part 1 .........





China is in trouble and further devaluations of the Yuan now seem certain with news today of the manufacturing index falling yet again.

Thus their export driven economy suffers and they are now highly likely to devalue another 5% within a month.

I think this will be followed by another 10% on top of that by early 2016 for a total devaluation of 20%.

The level they will try to get back to chartwise is around 1.46



The Yuan rose a lot in the last decade hence the Chinese slowdown , China must and will act to get its exports earning US dollars again but more importantly keep its workers employed. Otherwise unrest could follow.






How does this affect Cyprotex ?




Well a lot of folks on this thread probably thought Cyprotex had made a mistake when it acquired Apredica and the Cellumen assets in Boston MA back in 2010.

The USA has been regarded as a graveyard for UK companies being the olde adage.

That acquisition catapulted Cyprotex into the Top CRO echelon of Toxicology service providers .... at a stroke. A meaty US government 5 year contract (still running) followed , one that required automated robotic platforms to satisfy ( see recent Cyprotex comments) in terms of speed of delivery , quantity and quality.

This was followed in 2014 by yet another USA acquisition , CeeTox.

CeeTox had been previously awarded a massive 5 year US government contract worth up to around $140 Millions in the area of Endocrine Disrupters, considerable time and money has been spent updating CeeTox offerings , work on this contract is now ongoing ( see recent Cyprotex comments) plus




So was buying in the USA a good idea ?


Time will tell is another olde adage , at the time of the acquisitions both of the companies had unique IP ....

this IP was what won them the USA government contracts in the first place and had cost well over $35 Millions to develop by Cellumen ($10M ) and CeeTox the rest.

Cyprotex bought the lot PLUS Apredica which was profit making at the time of its acquisition for a total of about $2.25M cash at todays rates plus CRX shares to the value of $2.5M (to Apredica owners, subsequently now sold).

BOTH of these former USA owned companies , operate in the same Labs , Watertown near Boston MA ( biggest Pharma BioTech hub in the USA) and in Kalamazoo MI




The USA was a couple of years ago the biggest revenue earner for Cyprotex , see page 22


this year 2015 , the UK and EU are very strong and the USA due to some slippage in getting new automated robitics/associated equipment like new Mass Specs together with the Cyprotex unique IP LABSYS running it.


Cyprotex USA has the ability to become the top revenue earner again as more government work flows together with inceased orders from other industries , Cosmetics, Healthcare , Chemical, Agrochemical and others that have to conform to coming changes in the regulatory environment that recent advances in Toxicology and Endocrine Disruptor testing using live human and animal cells have made possible.



Conclusions.


1. USA turnover and hence profits look set to rise in 2016

2. The $USD is rising due to China devaluation

3. The $USD looks set to rise further in 2016 as China devalues yet again

4. Earnings in £GDP from $USD strength should benefit Cyprotex

5. At some point Cyprotex UK and Cyprotex US might be sold off separately as they now are running as dual facilities in the most part (except for CeeTox )

In other words another USA company might want to acquire just the USA Cyprotex assets.

or

Another UK or EU company might want to acquire the Cyprotex UK assets which now include a fast developing Alderley Science Park Lab involved in new Transporter assays amongst other developments.

[buywell3] 20/8/2015 06:53

Charts paint the true picture in my opinion of what the Market thinks about a share , words don't do it for me


Here the red line will need to get broken as it will offer chart resistance , but none the less it indicates some reasonable upside potential

The blue line indicates that the market has taken a view that overall things are going better than the early years




free stock charts from uk.advfn.com


The green lines below I would suggest are potential buy out values if the numbers keep adding up for the next couple of years



free stock charts from uk.advfn.com


Note the increase in the upward angle of the long term bottom trading support line around 2008

The market likes the share a bit better since that year.


The top trading channel blue line is key as it again is a resistance line

When and if the share gets through it , the green lines are possible but not before unless someone gets the hots for this company

[buywell2] 19/8/2015 16:20

The results indicate that Full year turnover will be well over £14 Million as Cyprotex always do better in the 2nd half

So £14.5 Million for 2015

The Mkt Cap is sitting at £13.46M

Which if it stayed flat means a profitable company with a 5 years growth record in turnover and operating in what many , especially in the USA see as the right sweet-spot sector to be. Investors over there can't get enough of Biotech Life Sciences stuff paying silly money for start-ups.

Current valuations in smaller companies in this sector have ranged from an average of 3 times turnover + 20 times profits for one doing well to an average of 2 times turnover plus 10 times profits for one flat lining.

Cyprotex had a bad 2014.

But still managed to increase turnover.

2015 looks like it is going to be a year of recovery.

Giving clients what they want, getting more involved with cell based assays , creating a BioSciences division , and creating more predictive computer based IP like ChemPK which utilizes data from human clinical trials.

The move to Alderly Park and the creation of the new offerings in Transporter based assays which the FDA now want done , demonstrates the company is ahead of the curve in seeing what the FDA have coming down the road in the way of new assay requirements. Genotoxicty assays look like being the next area for in house release/development , these also should add to a BioSciences premium that a potential predator might pay in the future.

The website does look quite good now , easy to navigate , user friendly , and the idea of the blog area paying off when one looks at increased client numbers.

You get the feel that Cyprotex is getting a 'refresh' , a remodel , a new image with new offerings that are starting to more reflect not only what the authorities like the FDA , EPA and EMA require , but also what new clients want in new industries that are now using Cyprotex services.

Big Pharma , the bread and butter workwise of Cyprotex is also changing. Take a look at the gamut of takeovers recently in the last couple of years involving top 10 pharmas and Life Sciences or BioSciences smaller companies involved in cellular level developments in the creation and diagnostic testing of new drug compounds.

Cyprotex is positioning itself as it must , to meet the demand for new assays and testing at molecular levels that are increasingly required.

The staff look up to the challenge and recent additions look good fits.




Based upon a 2015 Turnover of £14.5M and a full year profit of £0.825M


As a growth stock in the right sector with a growing BioSciences Division

The takeout price should be 3 X 14.5M + 20 X £0.825M then devide by 2

This equates to .......... £43.5M + £16.5M = £60 Million devided by 2 = £30M
Plus a wildcard £?M for a IP premium

That is now , so the share is undervalued if things improve as the year goes on

Next year things should be even better as spending slows and profits accrue.

[buywell3] 19/8/2015 06:51

China and India have cheap labour so some companies have been using their CRO services for ADME Tox testing.

People on $3 a day can be used instead of costly robotics

It is surprising to read the names in the link below of several of the worlds top 10 pharmaceuticals that have used such a company in India.

Presumably because they quote cheaper prices than their USA and EU counterparts.

But is that a good business decision for such companies ?

Do these big pharmaceuticals carry out checks to see that CRO's in emerging economies such as China and India use FDA proper validated testing procedures ?

Validation testing takes time and costs a lot of money so CRO's in far flung places thousands of miles away from the FDA in the USA might think they can do their own thing.

Pharmaceuticals lose $Billions on drugs that get withdrawn due to both lawsuits,lost sales and wasted time and money spent developing a new molecular compound that does harm or causes death to humans when it finally gets used after FDA approval.

You might think saving a few bucks getting ADME Tox pre-clinical testing carried out by CRO's in India for example , that do not use validated testing methods might be contravening their company risk management strategy .

The FDA stipulate the use of validated testing methods that satisfy CGMP (current good manufacturing practice) requirements. The FDA also considers contractors (CRO's) as ''extensions of the manufacturers own facility'' which seems to suggest that big pharmaceuticals have to check that the CRO's they pick are not just the cheapest , but do the job properly and to FDA standards.

This I found surprising




Could this be a one off ?

Have big pharmaceuticals made an error of judgement based upon ignorance or being too trusting of what foreign based CRO's tell them ?

This gives the answer

[ron64] 18/8/2015 16:41

Nice 300,000 buy after time

[johnwall] 18/8/2015 12:35

Encouraging results and I was thinking of re-acquiring a holding here until I was reminded of the Convertible Loan Notes.

Could someone please explain the practical effect of the CLNs for holders of the ordinary shares. I've read note 5 of the accounts several times and am struggling to get my head around the impact of the 'derivative' component. It seems to put a cap, or at least a drag, on any rise in the share price since the more the share price goes up the bigger the charge in the accounts. Or have I got that wrong???

Thanks in advance if anyone can shed light on this.

[saltaire111] 18/8/2015 11:34

Very strong results. I was a little sceptical about the level in investment they made in premises etc. but we can see that this is really paying off. Should be set fair now for substantial growth in profitability.

Considering buying more.
Salty

[skinny] 18/8/2015 07:07

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today reports its interim results for the half year to 30 June 2015.


Financial Highlights

· Revenues up 28% to £6.93 million (H1 2014: £5.41 million).
· Gross margins were 76.7% (H1 2014: 78.7%, FY 2014: 75.0%).
· Operating profit of £0.36 million (H1 2014: Operating loss £0.58 million).
· Underlying EBITDA^ of £1.10 million (H1 2014: £0.04 million).
· Cash of £4.13 million (H1 2014: £4.56 million, FY 2014: £2.93 million).

^ excluding share based payment charge

Operational Highlights

· The investment plan for all 4 sites which commenced in early 2014 and completed in early 2015 is now bearing fruit and has contributed significantly to the revenue growth seen in H1.
· Investment in a new drug transporter facility for the support of full drug-drug interaction studies for regulatory submission, QTof based metabolite identification and 3D tissue-based toxicology assays at our UK sites has been highly successful in revenue generation. Successful translocation of our existing toxicology facility to a second UK site at the BioHub, Alderley Park.
· Validation of a replica High Throughput (HT) ADME screening platform at our Watertown site has also been completed and the platform is now supporting large scale screening contracts for the US Government.
· Investment in upgrading our toxicology assays at our Kalamazoo site (formerly CeeTox) to bring them fully into OECD compliance has been completed and these assays, along with our proprietary SenCeeTox® skin sensitization assays have been well received by existing and new customers.
· Website upgrades including a new blog page have contributed to a noticeable improvement in the global recognition of the Cyprotex brand.
· 103 new customers in H1 2015 (111 in H1 2014).
· Successful completion and continued expansion of two large US Environmental Protection Agency (EPA) contracts.
· Largest customer is 12.3% (FY 2014: 7.8%) of revenues and represents a continuing large strategic deal with a major pharmaceutical company.

Post Period-End Highlights

· Expansion of Research & Development into regulatory genotoxicity services and the creation of a new Biosciences Division across all four global sites.

[p1nkfish] 21/7/2015 23:00

Reading between the lines on the 21st July 15 blog I think the US operations problems are well on the way to becoming history.

[p1nkfish] 14/7/2015 08:53

Excellent looking offering.

Only a matter of time before the key role crx plays in discovery and pre-approval test is recognised.

Anyone care to argue that this could treble within 3 years?

[p1nkfish] 14/7/2015 08:35

Good to see such a quiet board with positive news today.
Would guess the new product will be high margin.

[sharesoc] 02/6/2015 11:48

We are holding one of our popular Investor Masterclasses in Manchester so local investors and shareholders in CRX may be interested in attending as CRX is based nearby our venue...